ArticleBritish journal of cancer1998
Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.
Article in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 72 citations in OpenAlex.
- Review
- Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.International journal of molecular sciences · 2020Article
- Article
- Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.Cancer biology & therapy · 2017Article
- Article
- The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.Molecular cancer · 2012Article
- Molecular and genetic bases of neuroblastoma.International journal of clinical oncology · 2012Review
- The connections between neural crest development and neuroblastoma.Current topics in developmental biology · 2011Review
- The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.Genome medicine · 2009Article
- Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.British journal of cancer · 2007Article
- Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.Genome research · 2005Article
- Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma.British journal of cancer · 2004Article
- cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.BMC genomics · 2004Article
- SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.British journal of cancer · 2004Article
- Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.Cancer research · 2003Article
- Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.Oncogene · 2003Article
- Neuroblastoma tumour genetics: clinical and biological aspects.Journal of clinical pathology · 2001Review
- RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.Oncogene · 2001Article
- Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.British journal of cancer · 2001Article
- Neuroblastoma in monozygotic twins--a case of probable twin-to-twin metastasis.British journal of cancer · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is a heterogeneous childhood tumour of the sympathetic nervous system, in which deletions of chromosomal region 1p and amplification of the MYCN oncogene correlate with aggressive tumour behaviour. However, the majority of neuroblastoma tumours show neither of these aberrations, indicating that other chromosomal regions may be involved in tumorigenesis. Here, we report findings of loss of heterozygosity (LOH) on chromosome 3. In our neuroblastoma material, nine of 59 (15.3%) tested tumours showed allelic loss of chromosome 3p markers. We found significant clinical and biological differences between tumours with the loss of one entire chromosome 3 vs tumours with partial loss in chromosome region 3p. All children with tumours with whole chromosome 3 loss are long-term survivors, whereas all children with tumours showing partial 3p LOH have died from tumour progression. A consensus region found to be deleted in all the tumours with 3p deletions was defined by markers D3S1286 and D3S1295, i.e. 3p25.3-p14.3, distal to the FHIT gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.